Sanofi Pasteur Discusses Developing a Preventative C.diff. Infection Vaccine March 17, 2015 with C Diff Foundation’s ‘C diff Spores and More’ #CdiffRadio

cdiffRadioLogoMarch2015C. diff. Spores and More”

We invite you to join us in listening to this exciting episode on March 17th, 2015 and every Tuesday at the following times:

11a – 12p PT, 12p – 1pm MT, 1 pm – 2 pm CT,                              2 pm – 3 pm ET


Sanofi Pasteur, one of the leading vaccine manufacturers in the world, is currently conducting a Phase III clinical trial called Cdiffense in more than 20 countries across 5 continents to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary, symptomatic Clostridium difficile infection (CDI). The Cdiffense Phase III clinical program hopes to recruit up to 15,000 adults over 200 sites across the 20+ countries.

Sanofi Pasteur’s Dr. Christian Felter, MD is Associate VP, Global Medical Expert for Nosocomial Vaccines for Sanofi Pasteur based in Lyon, France. His focus is on their investigative Clostridium difficile vaccine.

Dr. Patricia J. Freda Pietrobon, PhD, Associate Vice President, R&D, Sanofi Pasteur, has over 25 years of experience in the Vaccine & Diagnostic industries and more then 20 years in leadership roles focusing on research & development of new vaccines.

Dr. Guy de Bruyn, Director for Clinical Development at Sanofi Pasteur, overseeing a large phase III vaccine trial for the prevention of Clostridium difficile infection in some 19 countries on 5 continents around the world that started in the U.S. in 2013.

Listen in on March 17th  as these three  Sanofi Pasteur professionals discuss the background of acquiring a C.difficile infection,  Sanofi Pasteur’s Phase III clinical trial called Cdiffense,  and data from the preventative vaccine in Phase II

Click on the link below to access the C. diff. Spores and More Show Page:


Take our show on the go………… a mobile app today